5 completed, 1 recruiting, 1 terminated. 3 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow ANX005: new trials by email Literature Review of ANX005 trials Research Report on ANX005
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) Tanruprubart - Guillain-Barre Syndrome | Phase 3 | Recruiting | Annexon, Inc. | 30 | 2025-09-12 | 2026-10-26 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) ANX005 - Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase 2 | Completed | Annexon, Inc. | 7 | 2021-11-10 | 2026-06-30 |
| Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) ANX005 - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Annexon, Inc. | 17 | 2021-01-15 | 2025-01-06 |
| Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome ANX005, Placebo - Guillain-Barre Syndrome | Phase 3 | Completed | Annexon, Inc. | 242 | 2020-12-17 | 2025-05-29 |
| An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease ANX005 - Huntington Disease | Phase 2 | Completed | Annexon, Inc. | 28 | 2020-09-29 | 2026-08-25 |
| A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) ANX005, Intravenous immunoglobulin - Guillain-Barré Syndrome | Phase 1 | Completed | Annexon, Inc. | 14 | 2020-01-29 | 2021-08-11 |
| Single Dose Study of ANX005 in Healthy Volunteers ANX005, IVIg, Placebos - Safety and Tolerability in Healthy Volunteers | Phase 1 | Terminated | Annexon, Inc. | 27 | 2016-12-01 | 2020-08-20 |
Guillain-Barre Syndrome (3) · Amyotrophic Lateral Sclerosis (1) · Huntington Disease (1)
Annexon, Inc. (7)
United States (4) · Australia (2) · Bangladesh (2) · Denmark (2) · Austria (1) · Bulgaria (1) · Canada (1) · France (1) · Philippines (1) · Spain (1) · United Kingdom (1)
Benjamin Hoehn, MD (1) · Benjamin Hoehn, MD, PhD (1) · Jason Lickliter, MBBS PhD (1) · Sandy Calman, MD (1)
2025 (1)